Recent Updates
Recently added Catalysts
FENC Positive Sentiment Score: 75/100

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Thursday, December 12, 2024 1 min read
Key Takeaway: Fennec Pharmaceuticals announced its participation in the virtual H.C. Wainwright @ Home Fireside Chat Series on December 16, 2024. This involvement highlights the company's ongoing efforts to engage with investors. Fennec has achieved significant regulatory milestones with its product, PEDMARK, aimed at preventing platinum-induced ototoxicity in children. The company has secured approvals from the FDA, European Commission, and U.K. for its products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in an investor conference indicates proactive engagement with investors.
  • Fennec Pharmaceuticals has FDA and European approvals for PEDMARK and PEDMARQSI, showing regulatory progress.
  • The company has a focus on a unique product aimed at a specific medical need in pediatric patients.

Full Press Release Details

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.
To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be available on the Fennec website following the event.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI®. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Elixir Health Public Relations
lrocco@elixirhealthpr.com

Frequently Asked Questions

When is Fennec Pharmaceuticals participating in the Fireside Chat?

Fennec Pharmaceuticals will participate in the Fireside Chat on December 16, 2024, at 11:00 a.m. ET.

How can I access the Fennec Pharmaceuticals webcast?

You can access the webcast at https://investors.fennecpharma.com/events-and-presentations/events.

What is PEDMARK® designed to do?

PEDMARK® is developed to reduce the risk of platinum-induced ototoxicity in pediatric patients.

When did PEDMARK receive FDA approval?

PEDMARK received FDA approval in September 2022.

What exclusivity does PEDMARK have in the U.S.?

PEDMARK has received Orphan Drug Exclusivity in the United States.

Tags: FENC Viatris Investor Conferences Healthcare Fennec Pharmaceuticals investor conference PEDMARK FDA approval
Last updated: Dec 12, 2024